VIA Pharmaceuticals (VIAP) Announces License Agreement with Roche
More News related to VIAP
- VIA Pharmaceuticals (VIAP) To Be Delisted January 4, 2010; Expects To Be Eligible For OTC Bulletin Board
- VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
- VIA Pharmaceuticals, Inc. (VIAP) Receives Non-Compliance Notification From NASDAQ
- VIA Pharmaceuticals (VIAP) Receives Non-Compliance Notification From NASDAQ
- VIA Pharmaceuticals (VIAP) Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients
More News related to Corporate News
- Toyota's (TM) Carter Says All Dealers Nationally Have Pedal Fix
- Northrop Grumman (NOC) Wins $26.2M Contract from U.S. Navy for Shipboard Radar Systems
- BT Group (BT) Awarded $370M Three-Year Contract Estension with The DWP
- BT (BT) Awarded 3-year Contract Extension with The Department for Work and Pensions Worth minimum of $370 Million
- AOL Inc. (AOL) Joins MIT Media Lab Consortium
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP) announced exclusive, worldwide licensing agreements with Roche for two sets of compounds. The first was for Roche's thyroid hormone receptor (THR) beta agonist, a clinically ready candidate for the control of cholesterol, triglyceride levels and potential in insulin sensitization/diabetes. The second was for multiple compounds from Roche's preclinical diacylglycerol acyl transferase 1 (DGAT1) metabolic disorders program.
Under the terms of the agreements, VIA will assume control of all development and commercialization of the compounds, and will own exclusive worldwide rights for all potential indications. The agreements provide for milestone payments for development and royalties upon commercialization.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease.[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
